Replies to post #624576 on NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

False. Dr. Liau stated UCLA uses DCVax-L.

[learningcurve2020]

It's the oldest line in the biotech playbook. I recall PPHM saying the same thing to get retail jumping in. As I recall they received ten million for the IP. LOL.

[Red_Right_Hand]

And NWBO has disclosed many of these in the past. About 8 years ago there was the announcement of discussions for 3 trials with 3 companies. And none launched.

You mean eight years ago, in 2015, when NW did not have data from the P3 or the P2 combo trial to share with potential partners? When potential partners did not have access to NWs P3 or P2 combo trial data? Would be an awfully strange conversation if NW and their potential partners were having discussions today, without making any mention of the now-available data that is being packaged for imminent application for approval.

You know what they say, 'if you didn't do something eight years ago, then it's completely impossible for you to do it today under completely different circumstances.'

[The Danish Dude]

So Ex is now going all in on fronting the Adam Feuerstein/JC stickied manipulative lie, which has been refuted by half a dozen from UCLA.

ATL-DC is not DCVax-L.

How pathetic comes fud?!

It must be last call and panic hour for the fudders. Yesterdays bomb must've hit bulls eye right in the bear hive.

Hilarious!

https://knowwhatyouhold.com/t/atl-dc-is-dcvax-l/180

[Smitty5150]

I think you may have missed this, or just forgot. I am here to refresh your memory:

https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers

FDA approvals may move UCLA brain cancer and Alzheimer’s treatments from bench to bedside

A vaccine to treat glioblastoma called DCVax-L has been in development for several years. Linda Liau, MD, PhD, MBA, and a team of UCLA researchers were the first to investigate whether a patient’s own dendritic cells (a specialized type of immune cell) could be used to create a personalized treatment for the deadly cancer.

At UCLA, Dr. Liau and other researchers are now testing whether the vaccine would be more effective in combination with a PD-1 checkpoint inhibitor. Checkpoint inhibitors are a type of immunotherapy that work by blocking proteins that stop the immune system from attacking cancer cells. While the vaccine allows T-cells to get inside of the tumor, the checkpoint inhibitors may allow T-cells to be more functional and better attack the tumor cells.

Right from the UCLA website, not second-hand information.